Bio-Path (NASDAQ:BPTH) Coverage Initiated by Analysts at StockNews.com

Research analysts at StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTH) in a research report issued on Tuesday. The firm set a “sell” rating on the stock.

Separately, Roth Mkm increased their price objective on Bio-Path from $12.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, March 27th.

Bio-Path Price Performance

Bio-Path stock opened at $2.95 on Tuesday. Bio-Path has a one year low of $2.94 and a one year high of $44.80. The stock has a market capitalization of $2.01 million, a PE ratio of -0.07 and a beta of 0.36. The business’s fifty day moving average is $5.84 and its 200 day moving average is $8.63.

Bio-Path (NASDAQ:BPTH) last released its quarterly earnings data on Friday, March 8th. The company reported ($5.40) EPS for the quarter, meeting the consensus estimate of ($5.40). During the same period in the previous year, the firm earned ($10.60) EPS. As a group, sell-side analysts expect that Bio-Path will post -18.71 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in Bio-Path by 77.5% in the fourth quarter. Vanguard Group Inc. now owns 270,029 shares of the company’s stock worth $125,000 after purchasing an additional 117,914 shares during the last quarter. Walleye Capital LLC purchased a new position in Bio-Path in the third quarter worth about $77,000. Citadel Advisors LLC purchased a new position in Bio-Path in the third quarter worth about $35,000. Renaissance Technologies LLC purchased a new position in Bio-Path in the second quarter worth about $70,000. Finally, Virtu Financial LLC bought a new position in shares of Bio-Path in the first quarter worth about $38,000. 5.74% of the stock is owned by hedge funds and other institutional investors.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.